Catriona Tedford

Dr. Catriona Tedford

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2014 in Gut
Verified
Journal Article
Open access
PDF file
ECEdward Chambers
Edward Chambers
AVAlexander Viardot
Alexander Viardot
APArianna Psichas
Arianna Psichas
DMDouglas Morrison
Douglas Morrison
KMKevin Murphy
Kevin Murphy
GFGary Frost
Gary Frost
Objective The colonic microbiota ferment dietary fibres, producing short chain fatty acids. Recent evidence suggests that the short chain fatty acid propionate may play an important role in appetite regulation. We hypothesised that colonic delivery of propionate would increase peptide YY (PYY) and glucagon like peptide-1 (GLP-1) secretion in humans, and reduce energy intake and weight gain in overweight adults. Design To investigate whether propionate promotes PYY and GLP-1 secretion, a primary cultured human colonic cell model was developed. To deliver propionate specifically to the colon, we developed a novel inulin-propionate ester. An acute randomised, controlled cross-over study was used to assess the effects of this inulin-propionate ester on energy intake and plasma PYY and GLP-1 concentrations. The long-term effects of inulin-propionate ester on weight gain were subsequently assessed in a randomised, controlled 24-week study involving 60 overweight adults. Results Propionate significantly stimulated the release of PYY and GLP-1 from human colonic cells. Acute ingestion of 10 g inulin-propionate ester significantly increased postprandial plasma PYY and GLP-1 and reduced energy intake. Over 24 weeks, 10 g/day inulin-propionate ester supplementation significantly reduced weight gain, intra-abdominal adipose tissue distribution, intrahepatocellular lipid content and prevented the deterioration in insulin sensitivity observed in the inulin-control group. Conclusions These data demonstrate for the first time that increasing colonic propionate prevents weight gain in overweight adult humans. Trial registration number NCT00750438.

10 April 2019 in Gut
Verified
Journal Article
Open access
PDF file
ECEdward Chambers
Edward Chambers
CBClaire S Byrne
Claire S Byrne
DMDouglas Morrison
Douglas Morrison
KMKevin G Murphy
Kevin G Murphy
TPTom Preston
Tom Preston
GFGary Frost
Gary Frost
Objective To investigate the underlying mechanisms behind changes in glucose homeostasis with delivery of propionate to the human colon by comprehensive and coordinated analysis of gut bacterial composition, plasma metabolome and immune responses. Design Twelve non-diabetic adults with overweight and obesity received 20 g/day of inulin-propionate ester (IPE), designed to selectively deliver propionate to the colon, a high-fermentable fibre control (inulin) and a low-fermentable fibre control (cellulose) in a randomised, double-blind, placebo-controlled, cross-over design. Outcome measurements of metabolic responses, inflammatory markers and gut bacterial composition were analysed at the end of each 42-day supplementation period. Results Both IPE and inulin supplementation improved insulin resistance compared with cellulose supplementation, measured by homeostatic model assessment 2 (mean±SEM 1.23±0.17 IPE vs 1.59±0.17 cellulose, p=0.001; 1.17±0.15 inulin vs 1.59±0.17 cellulose, p=0.009), with no differences between IPE and inulin (p=0.272). Fasting insulin was only associated positively with plasma tyrosine and negatively with plasma glycine following inulin supplementation. IPE supplementation decreased proinflammatory interleukin-8 levels compared with cellulose, while inulin had no impact on the systemic inflammatory markers studied. Inulin promoted changes in gut bacterial populations at the class level (increased Actinobacteria and decreased Clostridia) and order level (decreased Clostridiales) compared with cellulose, with small differences at the species level observed between IPE and cellulose. Conclusion These data demonstrate a distinctive physiological impact of raising colonic propionate delivery in humans, as improvements in insulin sensitivity promoted by IPE and inulin were accompanied with different effects on the plasma metabolome, gut bacterial populations and markers of systemic inflammation.

23 November 2016 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
APAttilio Pingitore
Attilio Pingitore
ECEdward S. Chambers
Edward S. Chambers
THThomas Hill
Thomas Hill
IRInmaculada Ruz-Maldonado
Inmaculada Ruz-Maldonado
BLBo Liu
Bo Liu
SPShanta J. Jean Persaud
Shanta J. Jean Persaud

1 July 2016 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
CBClaire Byrne
Claire Byrne
ECEdward S Chambers
Edward S Chambers
HAHabeeb Alhabeeb
Habeeb Alhabeeb
NCNavpreet Chhina
Navpreet Chhina
DMDouglas Morrison
Douglas Morrison
GFGary Frost
Gary Frost
Background: Short-chain fatty acids (SCFAs), metabolites produced through the microbial fermentation of nondigestible dietary components, have key rol

11 August 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
ECEdward Chambers
Edward Chambers
CBClaire S. Byrne
Claire S. Byrne
ARAnnette Rugyendo Rd
Annette Rugyendo Rd
DMDouglas Morrison
Douglas Morrison
TPTom Preston
Tom Preston
GFGary Frost
Gary Frost
The short chain fatty acid (SCFA) propionate, produced through fermentation of dietary fibre by the gut microbiota, has been shown to alter hepatic metabolic processes that reduce lipid storage. We aimed to investigate the impact of raising colonic propionate production on hepatic steatosis in adults with non‐alcoholic fatty liver disease (NAFLD). Eighteen adults were randomized to receive 20 g/d of an inulin‐propionate ester (IPE), designed to deliver propionate to the colon, or an inulin control for 42 days in a parallel design. The change in intrahepatocellular lipid (IHCL) following the supplementation period was not different between the groups ( P = 0.082), however, IHCL significantly increased within the inulin‐control group (20.9% ± 2.9% to 26.8% ± 3.9%; P = 0.012; n = 9), which was not observed within the IPE group (22.6% ± 6.9% to 23.5% ± 6.8%; P = 0.635; n = 9). The predominant SCFA from colonic fermentation of inulin is acetate, which, in a background of NAFLD and a hepatic metabolic profile that promotes fat accretion, may provide surplus lipogenic substrate to the liver. The increased colonic delivery of propionate from IPE appears to attenuate this acetate‐mediated increase in IHCL.

1 January 2004 in Analytica Chimica Acta
Verified
Journal Article
Closed access
Ross GillandersRoss Gillanders
Ross Gillanders
CTCatriona Tedford
Catriona Tedford
PCP.J. Crilly
P.J. Crilly
RBR.T. Bailey
R.T. Bailey